Blueprint Medicines Corp. (2L9)
Market Open
28 Jul, 07:56
XFRA 
NASDAQ (NGS) Primary XFRA €
2. 20
-0.25
-10.2041%
€
- Market Cap
- P/E Ratio
- Div Yield
50 Volume
-8.6 Eps
€ 2.45
Previous Close Want to track 2L9 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
| Name | Time | Cons. EPS | Eps |
|---|---|---|---|
| | | - | - |
| | | - | - |
| | | - | - |
| | | - | - |
| | | - | - |
| | | - | - |
| | | - | - |
| | | - | - |
| | | - | - |
| | | - | - |
2L9 Earnings Reports FAQ
What is the earnings per share (EPS) for 2L9?
The current EPS is -8.6.
What is the company's earnings growth rate?
Blueprint Medicines Corp has not announced its next earnings release date. You can monitor upcoming announcements in Marketlog's earnings calendar or in the company profile.
When is the next earnings release date?
Blueprint Medicines Corp has not announced its next earnings release date.
What were the most recent quarterly earnings?
The most recent quarterly earnings for Blueprint Medicines Corp are not available at this time.
What is the price-to-earnings (P/E) ratio?
There is no P/E ratio for 2L9 at this time, as Blueprint Medicines Corp has no recent EPS data to calculate it.
